$SGEN

AI Analysis

Generated on May 11, 2026

AI Score
5/ 100
Strong Sell$SGEN

Seagen Inc.

$SGENNASDAQHealthcareLarge-Cap

Seagen was acquired by Pfizer in 2023 for its antibody-drug conjugate cancer treatments.

Market Cap
$0.0B
Revenue (TTM)
$0.0B
N/A
Net Income (TTM)
$0.0B
N/A
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend Yield
0.0%
52-Week Range
$0-$0
Beta
0.80
Dimension Scores
Fundamental
5
Technical
5
Sentiment
5
Risk / Reward
5
Momentum
5
FundTechSentRiskMome
Financial Health
Profitability
10weak
Growth
8weak
Liquidity
13strong
Solvency
7moderate
Efficiency
3moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $SGEN

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.